Livzon Pharmaceutical Group (XSEC:000513) Stock Valuation, Peer Comparison & Price Targets

Share Price vs Fair Value

What is the Fair Price of 000513 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 000513 (CN¥36.92) is trading below our estimate of fair value (CN¥82.59)

Significantly Below Fair Value: 000513 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 000513?

Key metric: As 000513 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 000513. This is calculated by dividing 000513's market cap by their current earnings.
What is 000513's PE Ratio?
PE Ratio	16.6x
Earnings	CN¥2.02b
Market Cap	CN¥29.80b

000513 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2x
Enterprise Value/EBITDA	7.2x
PEG Ratio	1.6x

Price to Earnings Ratio vs Peers

How does 000513's PE Ratio compare to its peers?

The above table shows the PE ratio for 000513 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	92.8x
002603 Shijiazhuang Yiling Pharmaceutical	192.8x	48.6%	CN¥28.5b
002821 Asymchem Laboratories (Tianjin)	37.7x	29.9%	CN¥28.4b
600518 Kangmei Pharmaceutical	131.3x	n/a	CN¥32.4b
600566 Hubei Jumpcan Pharmaceutical	9.4x	10.7%	CN¥26.7b
000513 Livzon Pharmaceutical Group	16.6x	10.2%	CN¥29.8b

Price-To-Earnings vs Peers: 000513 is good value based on its Price-To-Earnings Ratio (16.6x) compared to the peer average (91.6x).

Price to Earnings Ratio vs Industry

How does 000513's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 000513 is good value based on its Price-To-Earnings Ratio (16.6x) compared to the CN Pharmaceuticals industry average (30.8x).

Price to Earnings Ratio vs Fair Ratio

What is 000513's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

000513 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	16.6x
Fair PE Ratio	25.1x

Price-To-Earnings vs Fair Ratio: 000513 is good value based on its Price-To-Earnings Ratio (16.6x) compared to the estimated Fair Price-To-Earnings Ratio (25.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 000513 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	CN¥36.92	CN¥40.29 +9.1%	14.6%	CN¥46.50	CN¥31.45	n/a	6
Nov ’25	CN¥37.28	CN¥40.29 +8.1%	14.6%	CN¥46.50	CN¥31.45	n/a	6
Oct ’25	CN¥40.65	CN¥41.22 +1.4%	13.5%	CN¥46.50	CN¥32.91	n/a	6
Sep ’25	CN¥35.96	CN¥41.39 +15.1%	13.8%	CN¥47.50	CN¥32.91	n/a	6
Aug ’25	CN¥36.10	CN¥41.06 +13.7%	15.2%	CN¥47.50	CN¥30.95	n/a	6
Jul ’25	CN¥38.18	CN¥41.14 +7.7%	14.8%	CN¥47.50	CN¥31.43	n/a	6
Jun ’25	CN¥38.70	CN¥41.14 +6.3%	14.8%	CN¥47.50	CN¥31.43	n/a	6
May ’25	CN¥40.10	CN¥41.14 +2.6%	14.8%	CN¥47.50	CN¥31.43	n/a	6
Apr ’25	CN¥36.88	CN¥39.81 +8.0%	14.2%	CN¥47.50	CN¥32.00	n/a	6
Mar ’25	CN¥38.48	CN¥39.92 +3.7%	13.9%	CN¥47.50	CN¥32.00	n/a	6
Feb ’25	CN¥33.68	CN¥39.75 +18.0%	14.5%	CN¥47.50	CN¥31.00	n/a	6
Jan ’25	CN¥35.01	CN¥39.23 +12.1%	10.4%	CN¥44.10	CN¥31.00	n/a	6
Dec ’24	CN¥34.80	CN¥39.23 +12.7%	10.4%	CN¥44.10	CN¥31.00	n/a	6
Nov ’24	CN¥34.87	CN¥38.90 +11.6%	12.3%	CN¥44.10	CN¥29.00	CN¥37.28	6
Oct ’24	CN¥36.94	CN¥39.44 +6.8%	13.3%	CN¥46.00	CN¥29.00	CN¥40.65	6
Sep ’24	CN¥34.23	CN¥39.94 +16.7%	10.7%	CN¥46.00	CN¥32.00	CN¥35.96	6
Aug ’24	CN¥36.62	CN¥42.03 +14.8%	13.5%	CN¥50.00	CN¥32.00	CN¥36.10	6
Jul ’24	CN¥38.91	CN¥41.70 +7.2%	15.1%	CN¥50.00	CN¥30.00	CN¥38.18	6
Jun ’24	CN¥38.76	CN¥41.70 +7.6%	15.1%	CN¥50.00	CN¥30.00	CN¥38.70	6
May ’24	CN¥35.79	CN¥41.70 +16.5%	15.1%	CN¥50.00	CN¥30.00	CN¥40.10	6
Apr ’24	CN¥37.38	CN¥44.41 +18.8%	22.4%	CN¥62.00	CN¥30.00	CN¥36.88	6
Mar ’24	CN¥35.93	CN¥44.41 +23.6%	22.4%	CN¥62.00	CN¥30.00	CN¥38.48	6
Feb ’24	CN¥34.14	CN¥44.41 +30.1%	22.4%	CN¥62.00	CN¥30.00	CN¥33.68	6
Jan ’24	CN¥32.48	CN¥41.97 +29.2%	15.7%	CN¥50.00	CN¥30.00	CN¥35.01	5
Dec ’23	CN¥37.78	CN¥41.97 +11.1%	15.7%	CN¥50.00	CN¥30.00	CN¥34.80	5
Nov ’23	CN¥36.97	CN¥41.97 +13.5%	15.7%	CN¥50.00	CN¥30.00	CN¥34.87	5

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥51.8b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥32.19

7D

1.8%

1Y

12.2%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.7b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.87

7D

-5.5%

1Y

11.1%

Dong-E-E-JiaoLtd

CN¥37.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥58.18

7D

-0.4%

1Y

15.5%

Livzon Pharmaceutical Group Valuation